MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026

DA-1726 showed placebo-adjusted reductions of 13.5% in body weight and 68% in liver fat in a Phase 1 interim analysis.

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) announced that its DA-1726 abstract was accepted for a poster presentation at ObesityWeek 2026 on November 14.

The poster is titled “DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared With Retatrutide.” In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 showed placebo-adjusted reductions of 13.5% in body weight and 68% in liver fat, with reduced visceral and subcutaneous fat and relatively preserved lean mass. MetaVia plans a 48-week, non-biopsy Phase 2 study in Metabolic and Alcohol-Associated Liver Disease and Alcohol-Associated Liver Disease, targeted to begin in the second half of 2027.

4 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointDA-1726 body weight reduction was 13.5% placebo-adjusted in the Phase 1 Part 3B Day 109 interim analysis.
• Moderate pointDA-1726 liver fat reduction was 68% placebo-adjusted in the Phase 1 Part 3B Day 109 interim analysis.
• Moderate point. Forward-looking: it has not happened yet and may not happen.MetaVia targets second-half 2027 initiation of a 48-week, non-biopsy Phase 2 DA-1726 study in MetALD and ALD.
• Minor pointDA-1726 interim results included reduced visceral and subcutaneous fat with relatively preserved lean mass.

Negative

• None.

Key Terms

oxyntomodulin, glp1r, gcgr

3 terms

oxyntomodulin medical

"a novel dual oxyntomodulin (OXM) analog"

Oxyntomodulin is a naturally occurring gut hormone released after eating that reduces appetite and influences blood sugar and energy use, acting like a thermostat that helps dial down hunger and adjust the body's fuel handling. It matters to investors because drugs that mimic or boost this hormone are a major class of experimental treatments for obesity and diabetes; trial results, safety findings, and regulatory decisions around oxyntomodulin-based therapies can strongly affect company value and market opportunity.

glp1r medical

"targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors"

A GLP‑1 receptor is a protein on certain cells that responds to the hormone GLP‑1, helping control blood sugar and appetite; drugs that activate this receptor can lower glucose and promote weight loss. Investors watch GLP‑1 receptor (GLP‑1R) drugs because successful medicines targeting it can command large markets, shift treatment standards, and drive sales, regulatory reviews, and partnership or acquisition activity — like finding a better key for an important lock.

gcgr medical

"targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors"

GCGR is the cell-surface protein that binds the hormone glucagon, acting like a lock that opens when glucagon — a signal that raises blood sugar — fits into it. It matters to investors because medicines that block or activate this receptor are central to treatments for diabetes and metabolic disease, so progress, safety results, or regulatory decisions about GCGR-targeting drugs can strongly affect a drug developer’s value and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for a poster presentation at ObesityWeek^® 2026, taking place November 14-17, 2026, in Washington, DC.

Presentation Details:

• Title: DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared With Retatrutide
• Session: Gut Peptides, Appetite Signaling & Novel Therapeutics
• Presenting Author: Il Hoon Jeong, MS, Research Scientist, Dong-A ST Research Center 
• Poster Number: Poster-229
• Session Date: Saturday, November 14, 2026
• Session Time: 7:30-8:30 pm ET
• Session Location: Exhibit Hall BCD

A copy of the poster will be available on the Posters section of the MetaVia website after the presentation.

About DA-1726
DA-1726 is a novel GLP1R/GCGR dual agonist being developed to address various cardiometabolic indications, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), which is designed for once weekly, subcutaneous administration. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. It is engineered with a 3:1 GLP1R:GCGR potency ratio intended to balance the complementary effects of GLP1R activation on appetite and glucose control with GCGR activation on energy expenditure and fat breakdown. DA-1726 has a well understood mechanism and preclinical tissue-distribution studies have shown that it concentrates most heavily in adipose tissue and in the liver. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated a 13.5% placebo-adjusted reduction in body weight and a 68% placebo-adjusted reduction in liver fat, along with reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass. MetaVia is planning a Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, targeted to begin in the second half of 2027.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, engineered with a 3:1 GLP1R:GCGR potency ratio. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated placebo-adjusted reductions of 13.5% in body weight and 68% in liver fat, along with reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass. A Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, is targeted to begin in the second half of 2027. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). It acts directly in the liver on pathways involved in steatosis, inflammation and fibrosis, while GPR119 activation in the pancreas and gut also supports glucose and metabolic regulation. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects. MetaVia is advancing vanoglipel in combination with resmetirom as a once-daily oral combination therapy for MASH, with a Phase 2a proof-of-concept study targeted to begin in the first half of 2027.

For more information, please visit www.metaviatx.com.

Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability obtain, maintain, protect and/or enforce sufficient intellectual property rights to execute its commercial strategy; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of preclinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-announces-poster-presentation-on-da-1726-at-obesityweek-2026-302932700.html

SOURCE MetaVia Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What weight-loss and liver-fat results did MetaVia report for DA-1726?

DA-1726 demonstrated placebo-adjusted reductions of 13.5% in body weight and 68% in liver fat in a Phase 1 Part 3B interim analysis at Day 109. The analysis also showed reductions in visceral and subcutaneous fat, with relatively preserved lean mass.